ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

Sunil K. Joshi; Jamie M. Keck; Christopher A. Eide; Daniel Bottomly; Elie Traer; Jeffrey W. Tyner; Shannon K. McWeeney; Cristina E. Tognon; Brian J. Druker

doi:10.1038/s41375-020-0844-7

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

Sunil K. Joshi, Jamie M. Keck, Christopher A. Eide, Daniel Bottomly, Elie Traer, Jeffrey W. Tyner, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	2798-2804
Number of pages	7
Journal	Leukemia
Volume	34
Issue number	10
DOIs	https://doi.org/10.1038/s41375-020-0844-7
State	Published - Oct 1 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-020-0844-7

Cite this

@article{74ff0c5c8f4b42c6bd6448ed2390f29d,

title = "ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia",

author = "Joshi, {Sunil K.} and Keck, {Jamie M.} and Eide, {Christopher A.} and Daniel Bottomly and Elie Traer and Tyner, {Jeffrey W.} and McWeeney, {Shannon K.} and Tognon, {Cristina E.} and Druker, {Brian J.}",

note = "Funding Information: Acknowledgements We are extremely thankful to our patients for their time and precious tissue samples. We also thank the Oregon Health & Science University Massively Parallel Sequencing Shared Resource and Flow Cytometry Core for technical support, Nicola Long, Kevin Watanabe-Smith, and Beth Wilmot for analytical support, Elitza Koutleva for help with NanoString analysis, and Kevin Yee for critical review of our manuscript. Funding for this project was provided by the Howard Hughes Medical Institute (HHMI), Leukemia & Lymphoma Society, and the National Cancer Institute grant (1R01CA214428) awarded to BJD. BJD is also supported by the following grants from the National Cancer Institute (1U01CA217862, 5U01CA214116, 1U54CA224019). SKJ is supported by the ARCS Scholar Foundation, The Paul & Daisy Soros Fellowship, and National Cancer Institute (1F30CA239335-02). ET is supported by grants from the Leukemia & Lymphoma Society (LLS SCOR 7005-11), American Cancer Society (MRSG-17-040-01-LIB), and National Cancer Institute (1U54CA224019). JWT received grants from the V Foundation for Cancer Research, The Mark Foundation, Gabrielle{\textquoteright}s Angel Foundation for Cancer Research, and National Cancer Institute (1R01CA183947, 1U01CA217862, 1U54CA224019, 3P30CA069533).",

year = "2020",

month = oct,

day = "1",

doi = "10.1038/s41375-020-0844-7",

language = "English (US)",

volume = "34",

pages = "2798--2804",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

AU - Joshi, Sunil K.

AU - Keck, Jamie M.

AU - Eide, Christopher A.

AU - Bottomly, Daniel

AU - Traer, Elie

AU - Tyner, Jeffrey W.

AU - McWeeney, Shannon K.

AU - Tognon, Cristina E.

AU - Druker, Brian J.

N1 - Funding Information: Acknowledgements We are extremely thankful to our patients for their time and precious tissue samples. We also thank the Oregon Health & Science University Massively Parallel Sequencing Shared Resource and Flow Cytometry Core for technical support, Nicola Long, Kevin Watanabe-Smith, and Beth Wilmot for analytical support, Elitza Koutleva for help with NanoString analysis, and Kevin Yee for critical review of our manuscript. Funding for this project was provided by the Howard Hughes Medical Institute (HHMI), Leukemia & Lymphoma Society, and the National Cancer Institute grant (1R01CA214428) awarded to BJD. BJD is also supported by the following grants from the National Cancer Institute (1U01CA217862, 5U01CA214116, 1U54CA224019). SKJ is supported by the ARCS Scholar Foundation, The Paul & Daisy Soros Fellowship, and National Cancer Institute (1F30CA239335-02). ET is supported by grants from the Leukemia & Lymphoma Society (LLS SCOR 7005-11), American Cancer Society (MRSG-17-040-01-LIB), and National Cancer Institute (1U54CA224019). JWT received grants from the V Foundation for Cancer Research, The Mark Foundation, Gabrielle’s Angel Foundation for Cancer Research, and National Cancer Institute (1R01CA183947, 1U01CA217862, 1U54CA224019, 3P30CA069533).

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85085069384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085069384&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0844-7

DO - 10.1038/s41375-020-0844-7

M3 - Article

C2 - 32366937

AN - SCOPUS:85085069384

SN - 0887-6924

VL - 34

SP - 2798

EP - 2804

JO - Leukemia

JF - Leukemia

IS - 10

ER -

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this